Postoperative non-steroidal anti-inflammatory drug use and oncological outcomes of rectal cancer.
Journal
BJS open
ISSN: 2474-9842
Titre abrégé: BJS Open
Pays: England
ID NLM: 101722685
Informations de publication
Date de publication:
08 01 2021
08 01 2021
Historique:
received:
12
08
2020
accepted:
06
11
2020
entrez:
20
2
2021
pubmed:
21
2
2021
medline:
16
11
2021
Statut:
ppublish
Résumé
Non-steroidal anti-inflammatory drugs (NSAIDs) are known to suppress the inflammatory response after surgery and are often used for pain control. This study aimed to investigate NSAID use after radical surgical resection for rectal cancer and long-term oncological outcomes. A cohort of patients who underwent anterior resection for rectal cancer between 2007 and 2013 in 15 hospitals in Sweden was investigated retrospectively. Data were obtained from the Swedish Colorectal Cancer Registry and medical records; follow-up was undertaken until July 2019. Patients who received NSAID treatment for at least 2 days after surgery were compared with controls who did not, and the primary outcome was recurrence-free survival. Cox regression modelling with confounder adjustment, propensity score matching, and an instrumental variables approach were used; missing data were handled by multiple imputation. The cohort included 1341 patients, 362 (27.0 per cent) of whom received NSAIDs after operation. In analyses using conventional regression and propensity score matching, there was no significant association between postoperative NSAID use and recurrence-free survival (adjusted hazard ratio (HR) 1.02, 0.79 to 1.33). The instrumental variables approach, including individual hospital as the instrumental variable and clinicopathological variables as co-variables, suggested a potential improvement in the NSAID group (HR 0.61, 0.38 to 0.99). conventional modelling did not demonstrate an association between postoperative NSAID use and recurrence-free survival in patients with rectal cancer, although an instrumental variables approach suggested a potential benefit.
Sections du résumé
BACKGROUND
Non-steroidal anti-inflammatory drugs (NSAIDs) are known to suppress the inflammatory response after surgery and are often used for pain control. This study aimed to investigate NSAID use after radical surgical resection for rectal cancer and long-term oncological outcomes.
METHODS
A cohort of patients who underwent anterior resection for rectal cancer between 2007 and 2013 in 15 hospitals in Sweden was investigated retrospectively. Data were obtained from the Swedish Colorectal Cancer Registry and medical records; follow-up was undertaken until July 2019. Patients who received NSAID treatment for at least 2 days after surgery were compared with controls who did not, and the primary outcome was recurrence-free survival. Cox regression modelling with confounder adjustment, propensity score matching, and an instrumental variables approach were used; missing data were handled by multiple imputation.
RESULTS
The cohort included 1341 patients, 362 (27.0 per cent) of whom received NSAIDs after operation. In analyses using conventional regression and propensity score matching, there was no significant association between postoperative NSAID use and recurrence-free survival (adjusted hazard ratio (HR) 1.02, 0.79 to 1.33). The instrumental variables approach, including individual hospital as the instrumental variable and clinicopathological variables as co-variables, suggested a potential improvement in the NSAID group (HR 0.61, 0.38 to 0.99).
CONCLUSION
conventional modelling did not demonstrate an association between postoperative NSAID use and recurrence-free survival in patients with rectal cancer, although an instrumental variables approach suggested a potential benefit.
Identifiants
pubmed: 33609397
pii: 6137422
doi: 10.1093/bjsopen/zraa050
pmc: PMC7893477
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents, Non-Steroidal
0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of BJS Society Ltd.
Références
Dig Surg. 2016;33(2):129-35
pubmed: 26771669
Surg Endosc. 2019 Mar;33(3):879-885
pubmed: 29998389
Int J Colorectal Dis. 2020 Apr;35(4):695-704
pubmed: 32040733
Int J Epidemiol. 2016 Dec 1;45(6):1887-1894
pubmed: 28089956
World J Surg. 2017 Jan;41(1):47-55
pubmed: 27766396
Acta Oncol. 2018 Dec;57(12):1611-1621
pubmed: 30477372
Eur J Surg Oncol. 2017 Oct;43(10):1908-1914
pubmed: 28687432
Acta Oncol. 2013 Nov;52(8):1707-14
pubmed: 23786178
J Gastrointest Surg. 2016 Apr;20(4):776-82
pubmed: 26536884
Cancer Res. 2017 Apr 1;77(7):1548-1552
pubmed: 28330928
J Zhejiang Univ Sci B. 2009 Mar;10(3):219-29
pubmed: 19283877
JAMA Surg. 2015 Mar 1;150(3):223-8
pubmed: 25607250
Ann Surg Oncol. 2019 Nov;26(12):3826-3837
pubmed: 31313040
World J Surg. 2019 Mar;43(3):659-695
pubmed: 30426190
Int J Colorectal Dis. 2011 Jan;26(1):53-9
pubmed: 20922542
Clin Exp Metastasis. 2018 Apr;35(4):333-345
pubmed: 29335811
Microsurgery. 2006;26(3):131-6
pubmed: 16518804
Nat Rev Clin Oncol. 2018 Apr;15(4):205-218
pubmed: 29283170
Br J Surg. 2007 Oct;94(10):1285-92
pubmed: 17661309
Br J Surg. 2020 Jan;107(2):e161-e169
pubmed: 31595986
Eur J Epidemiol. 2017 Sep;32(9):765-773
pubmed: 28983736
Br J Anaesth. 2017 Oct 1;119(4):750-764
pubmed: 29121285
BMJ. 2012 Sep 26;345:e6166
pubmed: 23015299
J Gastrointest Surg. 2018 Aug;22(8):1418-1433
pubmed: 29589264
Br J Surg. 1982 Oct;69(10):613-6
pubmed: 6751457
Am J Surg. 2015 Aug;210(2):382-8
pubmed: 25890814
Dis Colon Rectum. 2019 Feb;62(2):248-256
pubmed: 30489321
Surgery. 2010 Mar;147(3):339-51
pubmed: 20004450